(VIANEWS) – Shares of ERYTECH PHARMA (CAC 40: ERYP.PA) jumped by a staggering 11.44% to €0.76 at 13:56 EST on Friday, after four sequential sessions in a row of losses. CAC 40 is sliding 0.28% to €7,005.98, following the last session’s upward trend. This seems, at the moment, a somewhat bearish trend exchanging session today.
ERYTECH PHARMA’s last close was €0.68, 69.82% below its 52-week high of €2.26.
About ERYTECH PHARMA
ERYTECH Pharma S.A., a clinical-stage biopharmaceutical company, develops red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. Its lead product candidate is eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target methionine cancers. The company was incorporated in 2004 and is headquartered in Lyon, France.
Earnings Per Share
As for profitability, ERYTECH PHARMA has a trailing twelve months EPS of €-3.99.
Volume
Today’s last reported volume for ERYTECH PHARMA is 81651 which is 87.59% below its average volume of 658432.
Moving Average
ERYTECH PHARMA’s worth is way above its 50-day moving average of €0.65 and way below its 200-day moving average of €0.85.
More news about ERYTECH PHARMA (ERYP.PA).
